Belgian consensus for Helicobacter pylori management 2023

R Garcés-Duran, S Kindt, K Kotilea, S François, G Rasschaert, A Smet, B Hauser, A Driessen, M Nkuize, A Burette, V Lamy, P Bontems, Hubert Louis, R Ntounda, V Y Miendje Deyi, F Mana

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
1 Downloads (Pure)

Abstract

Helicobacter pylori (H. pylori) infection causes
chronic gastritis, peptic ulcers and gastric cancer.
Although H. pylori prevalence is decreasing worldwide,
regional variations exist in Europe, with the lowest
infection prevalence in Northern Europe, and the highest
in Eastern and Southern Europe (1). Changes in the
treatment recommendations and the increasing available
evidence have justified the implementation of new
recommendations since last Belgian consensus in 1998
(2). Several non-H. pylori Helicobacter species (NH.
PYLORI-H), colonizing the stomach of domestic animals,
also have the ability to cause gastric disease in humans,
although to a lesser extent. These zoonotic NH. PYLORIH
are not the subject of the current recommendations
Original languageEnglish
Article number36842178
Pages (from-to)74-91
Number of pages18
JournalActa Gastro-Enterologica Belgica
Volume86
Issue number1
DOIs
Publication statusPublished - Jan 2023

Bibliographical note

Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

Keywords

  • Humans
  • Helicobacter pylori
  • Consensus
  • Belgium
  • Helicobacter Infections/drug therapy
  • Anti-Bacterial Agents/therapeutic use

Fingerprint

Dive into the research topics of 'Belgian consensus for Helicobacter pylori management 2023'. Together they form a unique fingerprint.

Cite this